STOCK TITAN

GT Biopharma Inc. - GTBP STOCK NEWS

Welcome to our dedicated page for GT Biopharma news (Ticker: GTBP), a resource for investors and traders seeking the latest updates and insights on GT Biopharma stock.

GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immuno-oncology products targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors. Leveraging its proprietary NK cell engager (TriKE) platform technology, the company is dedicated to advancing innovative therapeutics in the United States. With a primary focus on cancer treatment, GT Biopharma's TriKE platforms offer promising solutions for hematologic malignancies, sarcoma, and solid tumors.

Rhea-AI Summary
GT Biopharma announces positive preclinical data for GTB-5550 in prostate cancer. The TriKE molecule demonstrated improved tumor control and NK cell cytotoxicity, even in resistant lines and hypoxia. The findings support the TriKE technology and its potential in prostate cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
GT Biopharma announces third quarter 2023 results, plans to submit IND for GTB-3650 in Q4 2023, and has cash of $16 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
management
Rhea-AI Summary

GT Biopharma, Inc. (NASDAQ: GTBP) reported its fourth quarter and full-year 2022 results, revealing a net loss of $5.6 million in Q4, down from $18.0 million the previous year. Total cash and equivalents as of December 31, 2022, were $16.5 million, bolstered by a $6.5 million direct offering completed in early January 2023. The company has successfully reduced research and development expenses to $2.8 million in Q4 2022, significantly down from $6.7 million a year earlier. With current cash resources and cost-cutting measures, GT Biopharma anticipates funding operations into Q2 2024, aiming for IND clearance for lead asset GTB-3650 in the first half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.28%
Tags
-
Rhea-AI Summary

GT Biopharma, Inc. (NASDAQ: GTBP) announced a presentation by Dr. Jeffrey Miller, its Consulting Chief Medical Officer, at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023. The presentation will offer a corporate overview of GTBP’s innovative therapeutics based on their proprietary TriKE® NK cell engager platform, designed to enhance natural killer cell functionality in cancer treatment.

Dr. Miller's presentation is scheduled from 9:00 - 9:20 am ET, and the company will also hold 1x1 meetings during the event. Interested parties can register for the webcast here.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
conferences
-
Rhea-AI Summary

GT Biopharma (NASDAQ: GTBP) announced key advancements in its open letter to shareholders, underscoring progress in developing its TriKE® platform targeting cancers. The company is prioritizing its lead candidate, GTB-3650, having signed an agreement with Cytovance Biologics to expedite its IND submission expected in H1 2023. Moreover, GTB-5550 for solid tumors is also in development. The company remains well-capitalized, with cash to sustain operations through 2023, and recently appointed Dr. Jeff Miller as Consulting Chief Medical Officer. Additional presentations at major oncology meetings indicate ongoing engagement with the scientific community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
Rhea-AI Summary

GT Biopharma has entered into a definitive securities purchase agreement for a registered direct offering of 6,500,000 shares and warrants, priced at $1.00 each. The total gross proceeds are expected to be $6.5 million, to be used for general corporate purposes. The offering is managed by H.C. Wainwright & Co. and is anticipated to close around January 4, 2023. The warrants have a five-year term and can be exercised starting six months after issuance. This offering leverages a previously filed shelf registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags

FAQ

What is the current stock price of GT Biopharma (GTBP)?

The current stock price of GT Biopharma (GTBP) is $2.81 as of December 23, 2024.

What is the market cap of GT Biopharma (GTBP)?

The market cap of GT Biopharma (GTBP) is approximately 6.3M.

What is GT Biopharma Inc. focused on?

GT Biopharma is focused on developing and commercializing novel immuno-oncology products targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors.

What is GT Biopharma's proprietary platform technology?

GT Biopharma leverages its NK cell engager (TriKE) platform technology to develop innovative therapeutics for a varied range of disease areas, with a primary focus on cancer treatment.

What types of cancers does GT Biopharma's TriKE platforms target?

GT Biopharma's TriKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

What stage is GT Biopharma currently in?

GT Biopharma is a clinical-stage biopharmaceutical company, actively engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform.

What sets GT Biopharma apart in the biopharmaceutical industry?

GT Biopharma's innovative TriKE platforms and focus on immuno-oncology products position it as a key player in the development of effective treatments for various types of cancer.

GT Biopharma Inc.

Nasdaq:GTBP

GTBP Rankings

GTBP Stock Data

6.35M
1.96M
12.15%
67.52%
0.79%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO